Market Research Logo

Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2016

Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2016’, provides an overview of the Metastatic Renal Cell Carcinoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Metastatic Renal Cell Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Renal Cell Carcinoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Metastatic Renal Cell Carcinoma
  • The report reviews pipeline therapeutics for Metastatic Renal Cell Carcinoma by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Metastatic Renal Cell Carcinoma therapeutics and enlists all their major and minor projects
  • The report assesses Metastatic Renal Cell Carcinoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Metastatic Renal Cell Carcinoma
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Metastatic Renal Cell Carcinoma
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Metastatic Renal Cell Carcinoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Metastatic Renal Cell Carcinoma Overview
Therapeutics Development
Pipeline Products for Metastatic Renal Cell Carcinoma - Overview
Pipeline Products for Metastatic Renal Cell Carcinoma - Comparative Analysis
Metastatic Renal Cell Carcinoma - Therapeutics under Development by Companies
Metastatic Renal Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes
Metastatic Renal Cell Carcinoma - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Metastatic Renal Cell Carcinoma - Products under Development by Companies
Metastatic Renal Cell Carcinoma - Products under Investigation by Universities/Institutes
Metastatic Renal Cell Carcinoma - Companies Involved in Therapeutics Development
Acceleron Pharma, Inc.
Amgen Inc.
Argos Therapeutics, Inc.
Astellas Pharma Inc.
Bayer AG
Bionomics Limited
Bionovis SA
Bristol-Myers Squibb Company
Cellceutix Corporation
Celldex Therapeutics, Inc.
Cerulean Pharma, Inc.
Dr. Reddy's Laboratories Limited
EirGenix Inc.
Eisai Co., Ltd.
Eli Lilly and Company
Exelixis, Inc.
Gene Techno Science Co., Ltd.
Genor BioPharma Co., Ltd.
Immune Design Corp.
Immunicum AB
Incyte Corporation
Mabion SA
MedImmune, LLC
Merck & Co., Inc.
Merck KGaA
Millennium Pharmaceuticals Inc
Mycenax Biotech Inc.
NewLink Genetics Corporation
Novartis AG
Oncobiologics, Inc.
Ono Pharmaceutical Co., Ltd.
Panacea Biotec Limited
Peloton Therapeutics, Inc.
Pfizer Inc.
Prima BioMed Ltd.
Rexahn Pharmaceuticals, Inc.
Richter Gedeon Nyrt.
Seattle Genetics, Inc.
Sevion Therapeutics, Inc.
Syndax Pharmaceuticals Inc
Taiwan Liposome Company, Ltd.
Tocagen Inc.
TVAX Biomedical, Inc.
Tyrogenex, Inc.
Metastatic Renal Cell Carcinoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AGS-16C3F - Drug Profile
avelumab - Drug Profile
bevacizumab biosimilar - Drug Profile
bevacizumab biosimilar - Drug Profile
bevacizumab biosimilar - Drug Profile
bevacizumab biosimilar - Drug Profile
bevacizumab biosimilar - Drug Profile
bevacizumab biosimilar - Drug Profile
bevacizumab biosimilar - Drug Profile
bevacizumab biosimilar - Drug Profile
bevacizumab biosimilar - Drug Profile
bevacizumab biosimilar - Drug Profile
bevacizumab biosimilar - Drug Profile
BNC-105 - Drug Profile
cabozantinib s-malate - Drug Profile
capmatinib - Drug Profile
CDX-014 - Drug Profile
Cellular Immunotherapy for Metastatic Renal Cell Carcinoma - Drug Profile
Cellular Immunotherapy for Metastatic Renal Cell Carcinoma and Melanoma - Drug Profile
crizotinib - Drug Profile
CRLX-101 - Drug Profile
dalantercept - Drug Profile
durvalumab - Drug Profile
emibetuzumab - Drug Profile
entinostat - Drug Profile
flucytosine ER + vocimagene amiretrorepvec - Drug Profile
G-305 - Drug Profile
IMP-321 - Drug Profile
INCAGN-1876 - Drug Profile
Intuvax - Drug Profile
ipilimumab - Drug Profile
KM-3174 - Drug Profile
lenvatinib mesylate - Drug Profile
LY-2510924 - Drug Profile
Monoclonal Antibody Conjugate to Target G250 Antigen for Renal Cell Carcinoma - Drug Profile
nivolumab - Drug Profile
Orellanine - Drug Profile
panobinostat - Drug Profile
pazopanib hydrochloride + pembrolizumab - Drug Profile
pembrolizumab - Drug Profile
PT-2385 - Drug Profile
radium Ra 223 dichloride - Drug Profile
Recombinant Protein for Oncology - Drug Profile
rocapuldencel-T - Drug Profile
RX-0201 - Drug Profile
sapanisertib - Drug Profile
SGN-CD70A - Drug Profile
Small Molecules to Inhibit SCD1 for Metastatic Renal Cell Carcinoma - Drug Profile
SNX-5422 - Drug Profile
SVN-002 - Drug Profile
TLC-388 - Drug Profile
trebananib - Drug Profile
TVI-Kidney-1 - Drug Profile
varlilumab - Drug Profile
X-82 - Drug Profile
Metastatic Renal Cell Carcinoma - Dormant Projects
Metastatic Renal Cell Carcinoma - Discontinued Products
Metastatic Renal Cell Carcinoma - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Metastatic Renal Cell Carcinoma, H2 2016
Number of Products under Development for Metastatic Renal Cell Carcinoma - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2016
Metastatic Renal Cell Carcinoma - Pipeline by Acceleron Pharma, Inc., H2 2016
Metastatic Renal Cell Carcinoma - Pipeline by Amgen Inc., H2 2016
Metastatic Renal Cell Carcinoma - Pipeline by Argos Therapeutics, Inc., H2 2016
Metastatic Renal Cell Carcinoma - Pipeline by Astellas Pharma Inc., H2 2016
Metastatic Renal Cell Carcinoma - Pipeline by Bayer AG, H2 2016
Metastatic Renal Cell Carcinoma - Pipeline by Bionomics Limited, H2 2016
Metastatic Renal Cell Carcinoma - Pipeline by Bionovis SA, H2 2016
Metastatic Renal Cell Carcinoma - Pipeline by Bristol-Myers Squibb Company, H2 2016
Metastatic Renal Cell Carcinoma - Pipeline by Cellceutix Corporation, H2 2016
Metastatic Renal Cell Carcinoma - Pipeline by Celldex Therapeutics, Inc., H2 2016
Metastatic Renal Cell Carcinoma - Pipeline by Cerulean Pharma, Inc., H2 2016
Metastatic Renal Cell Carcinoma - Pipeline by Dr. Reddy's Laboratories Limited, H2 2016
Metastatic Renal Cell Carcinoma - Pipeline by EirGenix Inc., H2 2016
Metastatic Renal Cell Carcinoma - Pipeline by Eisai Co., Ltd., H2 2016
Metastatic Renal Cell Carcinoma - Pipeline by Eli Lilly and Company, H2 2016
Metastatic Renal Cell Carcinoma - Pipeline by Exelixis, Inc., H2 2016
Metastatic Renal Cell Carcinoma - Pipeline by Gene Techno Science Co., Ltd., H2 2016
Metastatic Renal Cell Carcinoma - Pipeline by Genor BioPharma Co., Ltd., H2 2016
Metastatic Renal Cell Carcinoma - Pipeline by Immune Design Corp., H2 2016
Metastatic Renal Cell Carcinoma - Pipeline by Immunicum AB, H2 2016
Metastatic Renal Cell Carcinoma - Pipeline by Incyte Corporation, H2 2016
Metastatic Renal Cell Carcinoma - Pipeline by Mabion SA, H2 2016
Metastatic Renal Cell Carcinoma - Pipeline by MedImmune, LLC, H2 2016
Metastatic Renal Cell Carcinoma - Pipeline by Merck & Co., Inc., H2 2016
Metastatic Renal Cell Carcinoma - Pipeline by Merck KGaA, H2 2016
Metastatic Renal Cell Carcinoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
Metastatic Renal Cell Carcinoma - Pipeline by Mycenax Biotech Inc., H2 2016
Metastatic Renal Cell Carcinoma - Pipeline by NewLink Genetics Corporation, H2 2016
Metastatic Renal Cell Carcinoma - Pipeline by Novartis AG, H2 2016
Metastatic Renal Cell Carcinoma - Pipeline by Oncobiologics, Inc., H2 2016
Metastatic Renal Cell Carcinoma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
Metastatic Renal Cell Carcinoma - Pipeline by Panacea Biotec Limited, H2 2016
Metastatic Renal Cell Carcinoma - Pipeline by Peloton Therapeutics, Inc., H2 2016
Metastatic Renal Cell Carcinoma - Pipeline by Pfizer Inc., H2 2016
Metastatic Renal Cell Carcinoma - Pipeline by Prima BioMed Ltd., H2 2016
Metastatic Renal Cell Carcinoma - Pipeline by Rexahn Pharmaceuticals, Inc., H2 2016
Metastatic Renal Cell Carcinoma - Pipeline by Richter Gedeon Nyrt., H2 2016
Metastatic Renal Cell Carcinoma - Pipeline by Seattle Genetics, Inc., H2 2016
Metastatic Renal Cell Carcinoma - Pipeline by Sevion Therapeutics, Inc., H2 2016
Metastatic Renal Cell Carcinoma - Pipeline by Syndax Pharmaceuticals Inc, H2 2016
Metastatic Renal Cell Carcinoma - Pipeline by Taiwan Liposome Company, Ltd., H2 2016
Metastatic Renal Cell Carcinoma - Pipeline by Tocagen Inc., H2 2016
Metastatic Renal Cell Carcinoma - Pipeline by TVAX Biomedical, Inc., H2 2016
Metastatic Renal Cell Carcinoma - Pipeline by Tyrogenex, Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Metastatic Renal Cell Carcinoma - Dormant Projects, H2 2016
Metastatic Renal Cell Carcinoma - Dormant Projects (Contd..1), H2 2016
Metastatic Renal Cell Carcinoma - Dormant Projects (Contd..2), H2 2016
Metastatic Renal Cell Carcinoma - Dormant Projects (Contd..3), H2 2016
Metastatic Renal Cell Carcinoma - Dormant Projects (Contd..4), H2 2016
Metastatic Renal Cell Carcinoma - Discontinued Products, H2 2016
List of Figures
Number of Products under Development for Metastatic Renal Cell Carcinoma, H2 2016
Number of Products under Development for Metastatic Renal Cell Carcinoma - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report